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Preliminary Results
So far we have been able to successfully:
• Amplify human Semenogelin 1 fragments Ia, IIa, IIIa
• Purify and digest amplified fragments
• Optimize amplification and ensure complete digest
• Move amplicons into transfer vector and confirm via 
sequencing
- Create stocks of culture for storage
• Digest fragments out of transfer vector
• Cloned all fragments into the pScript expression vector
- Observed plate growth
- Confirmed via sequencing
The work done so far has created an optimized method 
for the consistent amplification of the Semenogelin 1 
fragments and a method to ensure complete digestion of 
the fragments before transformation. The transfer vector 
has also been very successful in accepting the fragments 
for large scale growth and further transformations.
• Methods are equally useful for Semenogelin 2
Transfected segments into human 293T cells to test 
expression with no observable protein production
• Protocols and antibodies can be altered to try and 
optimize the process
Discussion & Conclusions 
• Repeat processes with Human Semenogelin 2
• Double check all sequences for error
• Optimize transfection process to get proper expression 
of protein (using full length SEMG1 gene)
• Test commercially available antibodies for their ability 
to detect the semenogelin fragments and whole  
SEMG1c ene
• Determine an appropriate method for the optimized 
creation of antibodies and test their ability of 
detection
Future Directions
Methodology
The semenogelin proteins (SEMG1 and SEMG2) make up nearly 
50% of the total protein in semen, and protect spermatozoa by 
undergoing non-covalent crosslinking to form the coagulum after 
ejaculation.
This abundance makes the semenogelins effective markers for the 
detection of semen even when whole spermatozoa are not present.
Semenogelin can also be used to detect the presence of seminal 
fluid in suspected cases of sexual assault. By optimizing methods 
for creating peptide fragments of the semenogelin proteins, we can 
create novel antibodies for improved detection of human semen.
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Figure 4: Agarose gel of amplified human SEMG1
segment IIa in quadruplicate samples (A-D), 
stained with ethidum bromide.
Figure 7: Patch plate of human 
SEMG1 IIIa fragments cloned 
into pScript expression vector.
Figure 8: Photo of Human 293T Cells. 
Photo courtesy of Jennifer Vill (Jensen-
Seaman lab).
Figure 9: Expected protein expression 
results of SDS-PAGE gel, by Hannah 
Johnstonbaugh.
Figure 5: Patch plate of human SEMG1 IIIa 
fragments cloned into a transfer vector
Figure 6: Agarose gel of double 
digested human SEMG1 fragments
100 bp
Ladder
SEMG1 Ia SEMG1 IIIaSEMG1 IIa
• With fragments confirmed in a transfer vector, a 
double digest using EcoR1 and HindIII will allow for 
the movement into an expression vector
• Lower bands are the confirmed isolated fragments 
and can be purified via gel purification
• Segments again transferred to a mammalian 
expression vector to allow to the production of 
semenogelin protein
• Fragments cultured in HEK-293T cells and expression 
monitored using and SDS-Page gel and western blot 
assays
Figure 1: Interactions between the structural SEMG1 and SEMG2 proteins (secreted by 
the seminal vesicles) and the enzymes TGM4, ACPP, and KLK3 (secreted by the prostate).
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Figure 3: Diagram of fragments chosen to be amplified and tested for expression.
Four total fragments were chosen to be amplified and tested. Each segment was 
amplified from the start codon through the end of a specific segment of the gene. 
Chosen amplicons consisted of the start codon through the Ia, IIa, and IIIa 
segments, as well as the full length semenogelin 1 gene.
Each segment was amplified and worked in parallel
